<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03420430</url>
  </required_header>
  <id_info>
    <org_study_id>GL-ONC1-021</org_study_id>
    <nct_id>NCT03420430</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care</brief_title>
  <official_title>Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genelux Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genelux Corporation</source>
  <brief_summary>
    <textblock>
      GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical&#xD;
      trial. Expanded access is intended to treat individual patients with advanced stage cancers,&#xD;
      including blood cancer, with no standard of care options for treatment. Potential patients&#xD;
      will be evaluated individually depending on GL-ONC1 product supply.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)</condition>
  <condition>Acute Myeloid Leukemia (6 Patients)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GL-ONC1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of advanced cancers with no standard of care option for treatment.&#xD;
&#xD;
          -  Willing and able to provide written, signed informed consent.&#xD;
&#xD;
          -  Use of adequate contraception.&#xD;
&#xD;
          -  Negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have not recovered from severe adverse events from prior therapy.&#xD;
&#xD;
          -  Major surgery occurred within 28 days prior to treatment.&#xD;
&#xD;
          -  Known immune system disorders such as HIV, or active hepatitis B or C infection.&#xD;
&#xD;
          -  Clinically significant cardiac disease (New York Heart Association Class III or IV).&#xD;
&#xD;
          -  Have received prior therapy with an oncolytic virus of any type.&#xD;
&#xD;
          -  Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia&#xD;
             immunoglobulin, imatinib, ST-246).&#xD;
&#xD;
          -  Have known allergy to ovalbumin or other egg products.&#xD;
&#xD;
          -  Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any&#xD;
             unhealed skin wounds or ulcers) as assessed by the treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.genelux.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

